anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Mothers with anxiety and/or depression (N=60) receive no intervention. Assessment point only T0.
The purpose of this study is to evaluate and compare the relative bioavailability of Quinine Sulfate 324 mg capsules, manufactured by the Mutual Pharmaceutical Company, to Quinine Sulphate 300 mg tablets, manufactured by the Government Pharmaceutical Organization, Bangkok Metropolis, Thailand, after single oral dose administration under fasting conditions. An additional purpose of this study is to evaluate the effect of food on the Mutual Pharmaceutical Company product.

Twenty-seven healthy, non-smoking, non-obese, male and female volunteers at least 18 years of age will be randomly assigned in crossover fashion to receive each of three dosing regimens in sequence with a 7 day washout period between dosing periods. In each of the three dosing periods, after a fast of at least 10 hours, subjects will receive one dose of one of the three test products (treatment A - quinine sulfate capsules 324 mg, treatment B - quinine sulphate tablets 300 mg, treatment C - quinine sulfate capsules 324 mg administered thirty minutes after the initiation of a standardized, high-fat breakfast). Subjects will fast for 4 hours after dosing. Blood samples will be drawn from all participants before dosing and for 48 hours post-dose at times sufficient to adequately define the pharmacokinetics of quinine sulfate under fed and fasting conditions and quinine sulphate under fasting conditions. Sitting blood pressure and heart rate will be obtained prior to dosing and at 1, 2, 4 and 12 hours post-dose and upon completion of the study. An electrocardiogram will be recorded at check-in and at 2, 4, 6, 12, and 24 hours post-dose. Subjects will be monitored throughout their participation in the study for adverse reactions.
For the tests, the volunteers used the access device (Leap Motion) and a computer that were previously installed. The intervention was composed by 8 sessions of 15 minutes each, where the volunteers used a virtual environment attached it to a Leap Motion, which is a sensor that allows to capture the movements that are produced by the hands and reproduce them in a computer through a 3D virtual environment in order to stimulate the execution of their finer movements. The strength (Jamar) and motor coordination (wooden box) evaluations were made in the first, fourth and eighth sessions with the objective of checking the gain progression or not of motion coordination and grip strength.
Use of cinnamon and its extract (I) for the reduction of the energy consumption with the food, is new. An independent claim is also included for a medicament or dietetic food comprising (I) for the reduction of the energy consumption with the food. ACTIVITY : Anorectic; Antidiabetic; Ophthalmological; Neuroprotective. MECHANISM OF ACTION : Alpha amylase inhibitor. The ability of (I) to inhibit alpha amylase was tested in vitro using biological assays. The result showed that (I) exhibited the inhibiting activity of 30 mu g/ml.
An 89-year-old woman presented with chronic pain and foreign body sensation in a healthy-appearing anophthalmic socket. Computed tomography of the orbits showed hyperdense, cystic lesions superior and posterior to the orbital implant. Orbital exploration was performed; the orbital implant and lesions were removed. Histopathology revealed cystic structures composed of fibrocellular tissue lined with histiocytes and multinucleated giant cells, consistent with pseudocysts. Postoperatively, the patient noted the resolution of her symptoms. While the etiology of the pseudocysts remains unclear, we hypothesize that the answer can be traced back to the original surgery. The cysts may have formed after extravasation of fluid or proteinaceous material from the eye, from glycerin on the donor sclera, or after introduction of foreign material during retrobulbar injection of local anesthesia. This is the first report of pseudocysts occurring in the orbit posterior to an implant.
Subjects will be sequentially assigned to start with propofol or propofol with remifentanil. Propofol will be started at a concentration of 0.5 µg/ml followed by incremental increases in the target effect-site concentrations of 1.5, 2, 2.5, 3, 4, 6, and 8 µg/ml until a MOAA/S score less than 2 is reached.
The second group will attend a group health education using a standard DESMOND method (10-12 patients for each session lasting for 6 hours over one day by certified DESMOND educator in the conference room of the health center). The HA1C blood test together with completing a brief questionnaire form measuring the Diabetes Self-Care Activities during the past three months will be done after 3 and, 6 months will be done.
Individuals will be advised that the start of their intervention will be delayed by 10 weeks. After 10 weeks individuals in the control condition will be given the opportunity to avail of an induction session in the gym and subsequently use the gym facilities for three sessions if they so desire. Participants will be asked to refrain from exercise for the 10 week study period.
Fatigue driving is one of the leading causes of traffic accidents, and the rapid and accurate detection of driver fatigue is of paramount importance for enhancing road safety. However, the application of deep learning models in fatigue driving detection has long been constrained by high computational costs and power consumption. To address this issue, this study proposes an approach that combines Self-Organizing Map (SOM) and Spiking Neural Networks (SNN) to develop a low-power model capable of accurately recognizing the driver's mental state. Initially, spatial features are extracted from electroencephalogram (EEG) signals using the SOM network. Subsequently, the extracted weight vectors are encoded and fed into the SNN for fatigue driving classification. The research results demonstrate that the proposed method effectively considers the spatiotemporal characteristics of EEG signals, achieving efficient fatigue detection. Simultaneously, this approach successfully reduces the model's power consumption. When compared to traditional artificial neural networks, our method reduces energy consumption by approximately 12.21-42.59%.
This invention provide novel compositions, methods and devices for sustained drug delivery. The microencapsulated sustained drug delivery compositions are deposited using oscillating needle apparatus oscillating at 10-12000 minutes per minutes. The injected compositions may undergo variety of physical chemical changes upon deposition. The physical and chemical changes enables improved drug encapsulation and sustained drug release. Also described are new methods to form polymer microparticles or polymer films/implants in situ inside the tissue. The invention also describes colored biodegradable microparticle based compositions wherein the compositions comprise drug encapsulated microparticles and coloring agent encapsulated microparticles mixed in any proportion. Medical applications of the compositions and methods described in this invention are also described.
Bacterial skin infections represent a significant health care burden. Cellulitis and erysipelas are rapidly spreading, painful, superficial skin infections, usually caused by streptococci or Staphylococcus aureus. Folliculitis is an infection of hair follicles mostly caused by S aureus. Simple folliculitis typically is self-limited. Topical benzoyl peroxide is a first-line nonantibiotic treatment. Mupirocin and clindamycin are topical antibiotic options. For treatment-resistant cases, oral cephalexin or dicloxacillin is an appropriate option. Impetigo is a common, self-limited infection in children. Bullous impetigo is caused by S aureus, and nonbullous impetigo is caused by beta-hemolytic streptococci, S aureus, or both. In most cases, topical mupirocin or retapamulin (Altabax) is effective. Oral antibiotics should be considered for household outbreaks or patients with multiple lesions. Abscesses are red, painful collections of purulence in the dermis and deeper tissues caused by S aureus or polymicrobial infections. Furuncles are abscesses of a hair follicle, whereas carbuncles involve several hair follicles. In recurrent cases of these lesions, culture of the exudate is recommended. Abscess, furuncle, and carbuncle management consists of incision and drainage. Oral antibiotics are not necessary in most cases but should be prescribed for patients with severe immunocompromise or systemic signs of infection. In bacterial skin infections, methicillin-resistant S aureus coverage should be considered for patients with infections that have not improved with treatment.
Female subjects aged 10 to 16 will be recruited if they are diagnosed with AIS by standard standing long X-ray examinations, with Cobb angle larger or equal to 15°, without prior treatment for their AIS and been cleared for physical activity by their doctors. Subjects were excluded if they had (i) Cobb angle larger or equal to 40°, (ii) scoliosis with any known aetiologies such as congenital, neuromuscular, metabolic, and skeletal dysplasia, (iii) known endocrine and connective tissue abnormalities, (iv) known heart condition or other diseases that could affect the safety of exercise, (v) eating disorders or gastrointestinal malabsorption disorders, and (vi) currently taking medications that affecting their bone or muscle metabolism. All subjects will be recruited in the community.
INTRODUCTION: The success of health education programs heavily depends on the individuals' ability to comprehend information and apply it when making decisions regarding health. Low health literacy can lead to poor health in the context of both chronic and infectious diseases, as it influences a range of health-related behaviors. Little is known about infectious disease-related health literacy in Armenia and countries of similar socio-economic profiles. We aimed to quantify the levels of infectious disease-related health literacy and knowledge among the Armenian population and explore the underlying socio-economic factors.
MATERIALS AND METHODS: We conducted a nationwide phone survey among 3483 adults selected via stratified two-stage probability proportional to size sampling in 2021. Descriptive statistics, simple and multivariable regression were used for the analysis.
RESULTS: The average age of respondents was 49.5 years. The majority were female (71.0%) and had at least 12 years of schooling (70.5%). The mean literacy score was 5.64 out of 7 (SD:1.06). The mean infectious disease knowledge score was 2.48 out of 4 (SD:1.19). Younger age, female gender, higher level of education, city residence, being employed, and having higher monthly expenditures were associated with higher mean scores of infectious disease-related health literacy and knowledge. In multivariable linear regression analysis, all the socio-demographic characteristics remained significant for both dependent variables.
CONCLUSIONS: The study results revealed population groups with a higher infectious disease-related health literacy and knowledge. Interventions should focus on groups lagging behind to engage them in proper prevention practices to protect themselves and improve health status of Armenian population.
There is an urgent need for innovative approaches to pediatric obesity prevention and treatment. There is also a demand for targeted strategies that reduce attrition and improve compliance with obesity treatment. Intervening exclusively with parents of overweight children is a novel treatment approach, with demonstrated efficacy in reducing child body mass index (BMI) percentile. Motivational interviewing (MI), a brief communication style for exploring and resolving ambivalence about change, may enhance treatment engagement when implemented as part of obesity interventions. Further research investigating MI within pediatric obesity treatments is needed. In the current application, the investigators are examining whether MI implemented with parents for the treatment of their children's overweight can improve treatment effects. NOURISH+, a recently funded R01 (Nourishing Our Understanding of Role modeling to Improve Support and Health; PI, Mazzeo), is a culturally tailored parent intervention for overweight children ages 5-11. NOURISH+ targets lower-income, African American participants, a group at increased risk for pediatric overweight and associated complications, and builds on pilot work which yielded significant reductions in child BMI percentile. The investigators are adding an MI treatment into NOURISH+. Specifically, we will randomly select 60 parents at enrollment and investigate if adding two brief MI sessions prior to the NOURISH+ group intervention will enhance treatment effects. The investigators will be able to compare NOURISH+MI with participants from the two R01 treatment conditions (NOURISH+ and Control), matched on child ethnicity and gender. The investigators hypothesize that children whose parents participate in NOURISH+ MI will demonstrate lower attrition and greater compliance with NOURISH+, ultimately leading to greater treatment effects, compared with children whose parents are randomized to NOURISH+ or a control group.
The invention relates to an insulin nano transdermal delivery preparation and a preparation method thereof. The insulin nano transdermal delivery preparation takes recombinant human insulin as an active pharmaceutical ingredient and is a filled closed type transdermal preparation consisting of an anti-sticking layer, a drug-loaded layer and a back lining layer. The drug-loaded layer consists of nano recombinant human insulin, a carrier, a penetration enhancer and a plasticizer. The nano recombinant human insulin is obtained by dissolving insulin in a solvent, adding water-soluble auxiliary agents including liposome, chitosan, HPMC (hydroxy propyl methyl cellulose) and the like and an aqueous solution of a freeze-drying protective additive, performing low-temperature high-speed stirring and then performing freeze-drying. The patch disclosed by the invention realizes transdermal noninvasive administration through nano-scale combination of insulin and the carrier to ensure that the bioavailability of the insulin is greatly improved; the patch has the advantages of high transdermal absorption rate, fast response, good treatment effect and good product stability, does not have anaphylactic and toxic reactions to skins, and has the characteristics of good safety, small side effect and convenience in use. The preparation method of the insulin nano transdermal patch disclosed by the invention is simple, low in production cost, and easy to magnify.
In an exemplary embodiment, a server receives from a communication device (i) an identifier of a patient and (ii) a login credential associated with an individual. The server makes a determination based on the login credential that the individual is authorized to access a patient record of the patient. Subsequent to making the determination, the server prepares an assessment based on the patient record, and provides the assessment to the communication device. The assessment includes a measurement. The server subsequently receives a measurement result from the communication device and updates the patient record based on the measurement result. The server prepares a care plan based on the patient record and provides the care plan to the communication device. The care plan includes a task. The server subsequently receives a task status from the communication device and updates the patient record based on the task status.
Holmium Xpeeda side firing fibre was introduced and it stands apart from other available technologies as a combination of power and efficiency, which minimizes vaporization time. This technology seems to revolutionize utilization of the Holmium power and delivering more energy directly to the tissue, due to its capability of being in contact with the tissue. Moreover, hemostasis would be improved by the pulse reshaping technology with a wider pulse width, activated by a dedicated footswitch. Therefore, the Lumenis Pulse™ 100W will make prostate vaporesection procedures more precise, faster and efficient, with excellent hemostasis. Consequently, bleeding is minimal, tissue is easier to remove and patients can have their catheter removed faster.
This is a phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. Niraparib is an orally active PARP inhibitor. Niraparib (in a 2:1 ratio) will be administered once daily continuously during a 21-day cycle. Physician's choice will be administered on a 21-day cycle. Health-related quality of life will be measured. The safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), and safety laboratory values.
The invention relates to the technical field of medicines, discloses a compound for treating leukemia and a preparation method thereof and specifically discloses a Nelarabine crystalline compound and a preparation method thereof. The Nelarabine crystalline compound provided by the invention is different from the existing Nelarabine crystalline compound, has good solubility in water, and has stability, bioavailability, yield and purity superior to those of the existing Nelarabine crystalline compound. An X-ray powder diffraction pattern obtained by Cu-K alpha ray measurement is shown in the description. The invention also discloses a preparation method of the Nelarabine crystalline compound. The preparation method comprises the following steps: taking a Nelarabine crude product, heating and dissolving the Nelarabine crude product through a mixed solution, stirring the mixture for 1 to 3 hours, cooling the mixture to -10 DEG C, carrying out standing crystallization, carrying out suction filtration, washing the crystals through a small amount of petroleum ether twice and carrying out vacuum drying to obtain the Nelarabine crystalline compound. The preparation method is simple and is suitable for large-scale production.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to peroral pharmaceutical medicinal form containing acid-sensitive inhibitor of proton pump and one or some antacid substances or alginate in fixed composition where proton pump inhibitor is protected by enterosoluble coating layer and optional separative layer between proton pump inhibitor and enterosoluble coating. Fixed composition has a form of multilayer tablets, sachet or complex tableted medicinal forms. Invention relates to also methods of medicinal form preparing. New fixed composition is used especially for healing disorders associated with dyspepsia, for example, heartburn. EFFECT: simplified patient regimen and treatment schedule. 25 cl, 3 dwg, 10 ex
BACKGROUND: People with chronic pain experience variability in their trajectories of pain severity. Previous studies have explored pain trajectories by clustering sparse data; however, to understand daily pain variability, there is a need to identify clusters of weekly trajectories using daily pain data. Between-week variability can be explored by quantifying the week-to-week movement between these clusters. We propose that future work can use clusters of pain severity in a forecasting model for short-term (eg, daily fluctuations) and longer-term (eg, weekly patterns) variability. Specifically, future work can use clusters of weekly trajectories to predict between-cluster movement and within-cluster variability in pain severity.
OBJECTIVE: This study aims to understand clusters of common weekly patterns as a first stage in developing a pain-forecasting model.
METHODS: Data from a population-based mobile health study were used to compile weekly pain trajectories (n=21,919) that were then clustered using a k-medoids algorithm. Sensitivity analyses tested the impact of assumptions related to the ordinal and longitudinal structure of the data. The characteristics of people within clusters were examined, and a transition analysis was conducted to understand the movement of people between consecutive weekly clusters.
RESULTS: Four clusters were identified representing trajectories of no or low pain (1714/21,919, 7.82%), mild pain (8246/21,919, 37.62%), moderate pain (8376/21,919, 38.21%), and severe pain (3583/21,919, 16.35%). Sensitivity analyses confirmed the 4-cluster solution, and the resulting clusters were similar to those in the main analysis, with at least 85% of the trajectories belonging to the same cluster as in the main analysis. Male participants spent longer (participant mean 7.9, 95% bootstrap CI 6%-9.9%) in the no or low pain cluster than female participants (participant mean 6.5, 95% bootstrap CI 5.7%-7.3%). Younger people (aged 17-24 y) spent longer (participant mean 28.3, 95% bootstrap CI 19.3%-38.5%) in the severe pain cluster than older people (aged 65-86 y; participant mean 9.8, 95% bootstrap CI 7.7%-12.3%). People with fibromyalgia (participant mean 31.5, 95% bootstrap CI 28.5%-34.4%) and neuropathic pain (participant mean 31.1, 95% bootstrap CI 27.3%-34.9%) spent longer in the severe pain cluster than those with other conditions, and people with rheumatoid arthritis spent longer (participant mean 7.8, 95% bootstrap CI 6.1%-9.6%) in the no or low pain cluster than those with other conditions. There were 12,267 pairs of consecutive weeks that contributed to the transition analysis. The empirical percentage remaining in the same cluster across consecutive weeks was 65.96% (8091/12,267). When movement between clusters occurred, the highest percentage of movement was to an adjacent cluster.
CONCLUSIONS: The clusters of pain severity identified in this study provide a parsimonious description of the weekly experiences of people with chronic pain. These clusters could be used for future study of between-cluster movement and within-cluster variability to develop accurate and stakeholder-informed pain-forecasting tools.
Those patients who are assigned to the control group will have the CHICA system but will NOT be cared for using the CHICA Type 2 Diabetes Module. The CHICA system will notify the physician of the child's BMI percentile on the physician worksheet. However, the CHICA system will not ask for any additional information related to risk factors for type 2 diabetes on the pre-screening form, no advice will be provided to the physician on the physician worksheet, nor will just-in-time documents or automated reminder calls be made available. Identification of patients at risk for type 2 diabetes and care of those patients will occur through routine practices for that clinic.
PURPOSE:To obtain a bathing agent composition having excellent skin care effect, by adding a component composed of an eggshell membrane to a bathing agent for foaming a carbon dioxide gas and controlling constant pH of bathing water in a bathtub. CONSTITUTION:A bathing agent for foaming a carbon dioxide gas, consisting essentially of a carbonate (e.g. sodium carbonate) and an organic acid (e.g. malic acid) is mixed with a membrane component existing inside of eggshell of a bird such as chicken, quail or duck. The concentration of the membrane component is 0.001-1,000ppm calculated as the membrane component (0.2mg-200g in 200l bathing water). The bathing agent is adjusted to have pH>=6, preferably pH6-10 when dissolved in water in a bathtub, and prepared into tablets, powder or granule. The bathing agent has high skin care effect and is inexpensively obtained by adding an eggshell membrane component and controlling bathing water at pH>=6.